Collection of Peripheral Blood Progenitor Cells in One Day is Associated with Decreased Donor Toxicity compared to Two Days in Unrelated Donors. Biol Blood Marrow Transplant. 2020.
The impact of donor type on outcomes and cost of allogeneic hematopoietic cell transplant for pediatric leukemia: a merged CIBMTR and PHIS analysis: Pediatric acute leukemia transplant risks and utilization. Biol Blood Marrow Transplant. 2020.
Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury-Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant. JAMA Netw Open. 2020;3(1):e1918668.
Interferon-complement loop in transplant-associated thrombotic microangiopathy. Blood Adv. 2020;4(6):1166-1177..
Feasibility of continuous temperature monitoring in pediatric immunocompromised patients: A pilot study. Pediatr Blood Cancer. 2019:e27723..
Improving the Timeliness of Chemotherapy Administration in the Bone Marrow Transplant Unit. Biol Blood Marrow Transplant. 2019..
The natural history of BK polyomavirus and the host immune response after stem cell transplantation. Clin Infect Dis. 2019.
Quality Improvement Initiative to Reduce Nighttime Noise in a Transplantation and Cellular Therapy Unit. Biol Blood Marrow Transplant. 2019.
Antibiotic Exposure and Reduced Short Chain Fatty Acid Production after Hematopoietic Stem Cell Transplant. Biol Blood Marrow Transplant. 2018.
A Prospective Study of Alemtuzumab as a Second Line Agent for Steroid Refractory Acute Graft Versus Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplant. Biol Blood Marrow Transplant. 2016.
Terminal complement blockade after HSCT is safe without meningococcal vaccination. Biol Blood Marrow Transplant. 2016..